Screener
Arbutus Biopharma Corporation ABUS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Common shares | ||
| Authorized: Unlimited number without par value | ||
| Issued and outstanding: 196,947,757(December 31, 2025: 192,531,225) | 1,444,494 | 1,421,429 |
| Additional paid-in capital | 74,256 | 83,318 |
| Deficit | (1,210,378) | (1,380,073) |
| Accumulated other comprehensive loss | (48,195) | (48,098) |
| Total stockholders’ equity | 260,177 | 76,576 |
| Total liabilities and stockholders’ equity | $277,164 | $94,618 |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's total equity?
- Arbutus Biopharma Corporation (ABUS) reported total equity of $260.18M in Q1 2026.
- How has Arbutus Biopharma Corporation's total equity changed year-over-year?
- Arbutus Biopharma Corporation's total equity increased by 228.7% year-over-year, from $79.16M to $260.18M.
- What is the long-term trend for Arbutus Biopharma Corporation's total equity?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's total equity has grown at a -5.6% compound annual growth rate (CAGR), from $101.97M to $76.58M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Arbutus Biopharma Corporation's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude